These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 19302997

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
    Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Grégoire M, Porte H, Copin MC, Lassalle P.
    Clin Cancer Res; 2007 May 15; 13(10):2928-35. PubMed ID: 17504993
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
    Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J.
    Ann Thorac Surg; 2008 Jan 15; 85(1):265-72; discussion 272. PubMed ID: 18154821
    [Abstract] [Full Text] [Related]

  • 5. Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.
    Iwahori K, Osaki T, Serada S, Fujimoto M, Suzuki H, Kishi Y, Yokoyama A, Hamada H, Fujii Y, Yamaguchi K, Hirashima T, Matsui K, Tachibana I, Nakamura Y, Kawase I, Naka T.
    Lung Cancer; 2008 Oct 15; 62(1):45-54. PubMed ID: 18394747
    [Abstract] [Full Text] [Related]

  • 6. Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.
    Hollevoet K, Nackaerts K, Thimpont J, Germonpré P, Bosquée L, De Vuyst P, Legrand C, Kellen E, Kishi Y, Delanghe JR, van Meerbeeck JP.
    Am J Respir Crit Care Med; 2010 Mar 15; 181(6):620-5. PubMed ID: 20075387
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma.
    Creaney J, Dick IM, Segal A, Musk AW, Robinson BW.
    Lung Cancer; 2013 Dec 15; 82(3):491-8. PubMed ID: 24161718
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma.
    Shiomi K, Hagiwara Y, Sonoue K, Segawa T, Miyashita K, Maeda M, Izumi H, Masuda K, Hirabayashi M, Moroboshi T, Yoshiyama T, Ishida A, Natori Y, Inoue A, Kobayashi M, Sakao Y, Miyamoto H, Takahashi K, Hino O.
    Clin Cancer Res; 2008 Mar 01; 14(5):1431-7. PubMed ID: 18316566
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.
    Schneider J, Hoffmann H, Dienemann H, Herth FJ, Meister M, Muley T.
    J Thorac Oncol; 2008 Nov 01; 3(11):1317-24. PubMed ID: 18978568
    [Abstract] [Full Text] [Related]

  • 14. Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers.
    Maeda M, Hino O.
    Pathol Int; 2006 Nov 01; 56(11):649-54. PubMed ID: 17040286
    [Abstract] [Full Text] [Related]

  • 15. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
    Franceschini MC, Ferro P, Canessa PA, Battolla E, Dessanti P, Valentino A, Casolari L, Fontana V, Pezzi R, Fedeli F, Pistillo MP, Roncella S.
    Anticancer Res; 2014 Dec 01; 34(12):7425-9. PubMed ID: 25503183
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.
    Demir M, Kaya H, Taylan M, Ekinci A, Yılmaz S, Teke F, Sezgi C, Tanrikulu AC, Meteroglu F, Senyigit A.
    Lung; 2016 Jun 01; 194(3):409-17. PubMed ID: 27032653
    [Abstract] [Full Text] [Related]

  • 17. Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis.
    Cui A, Jin XG, Zhai K, Tong ZH, Shi HZ.
    BMJ Open; 2014 Feb 24; 4(2):e004145. PubMed ID: 24566531
    [Abstract] [Full Text] [Related]

  • 18. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
    Muley T, Dienemann H, Herth FJ, Thomas M, Meister M, Schneider J.
    J Thorac Oncol; 2013 Jul 24; 8(7):947-51. PubMed ID: 23777840
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology.
    Canessa PA, Franceschini MC, Ferro P, Battolla E, Dessanti P, Manta C, Sivori M, Pezzi R, Fontana V, Fedeli F, Pistillo MP, Roncella S.
    Cancer Invest; 2013 Jan 24; 31(1):43-50. PubMed ID: 23249166
    [Abstract] [Full Text] [Related]

  • 20. Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.
    Ferro P, Canessa PA, Battolla E, Dessanti P, Franceschini MC, Chiaffi L, Morabito A, Fontana V, Pezzi R, Fedeli F, Pistillo MP, Roncella S.
    Anticancer Res; 2013 Jun 24; 33(6):2707-13. PubMed ID: 23749930
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.